Compare EQR & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQR | CNC |
|---|---|---|
| Founded | 1993 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 18.7B |
| IPO Year | 1993 | 2001 |
| Metric | EQR | CNC |
|---|---|---|
| Price | $63.35 | $41.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 17 |
| Target Price | ★ $70.00 | $40.06 |
| AVG Volume (30 Days) | 2.1M | ★ 5.8M |
| Earning Date | 02-02-2026 | 02-03-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | ★ 24.49 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | $3,078,827,000.00 | ★ $167,680,000,000.00 |
| Revenue This Year | $5.10 | $32.55 |
| Revenue Next Year | $3.51 | $0.21 |
| P/E Ratio | $20.93 | ★ N/A |
| Revenue Growth | 4.69 | ★ 14.57 |
| 52 Week Low | $58.38 | $25.08 |
| 52 Week High | $75.86 | $66.81 |
| Indicator | EQR | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 65.22 |
| Support Level | $60.89 | $38.58 |
| Resistance Level | $64.20 | $40.15 |
| Average True Range (ATR) | 0.84 | 1.17 |
| MACD | 0.22 | 0.09 |
| Stochastic Oscillator | 79.10 | 91.01 |
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.